Drug Profile
Research programme: chimeric antigen receptors T cell therapies - AvenCell Europe
Latest Information Update: 06 Apr 2023
Price :
$50
*
At a glance
- Originator GEMoaB Monoclonals
- Developer AvenCell Europe
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 05 Apr 2023 Preclinical development is ongoing for Haematological malignancies in Germany (AvenCell Europe pipeline, April 2023)
- 05 Apr 2023 Preclinical development is ongoing for Solid tumours in Germany (AvenCell Europe pipeline, April 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Haematological malignancies in Germany (Parenteral)